Article
Chemical genetics strategy identifies an HCV NS5A inhibitor with a potent clinical effect.
Nature - 6 May 2010
Gao Min, Nettles Richard E, Belema Makonen, Snyder Lawrence B, Nguyen Van N, Fridell Robert A, Serrano-Wu Michael H, Langley David R, Sun Jin-Hua, O'Boyle Donald R, Lemm Julie A, Wang Chunfu, Knipe Jay O, Chien Caly, Colonno Richard J, Grasela Dennis M, Meanwell Nicholas A, Hamann Lawrence G
Abstract excerpt
The worldwide prevalence of chronic hepatitis C virus (HCV) infection is estimated to be approaching 200 million people. Current therapy relies upon a combination of pegylated interferon-alpha and ribavirin, a poorly tolerated regimen typically associated with less than 50% sustained virological response rate in those infected with genotype 1 virus. The development of direct-acting antiviral agents to treat HCV...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.